Shin Nippon Biomedical Laboratories Ltd represents values of innovation, excellence, and commitment to healthcare advancements. As a leading biomedical research company, they prioritize the development of high-quality pharmaceutical products and services. Shin Nippon Biomedical Laboratories Ltd embraces a corporate philosophy centered around dedication to improving global health through cutting-edge research, collaboration with industry experts, and a patient-centric approach. By leveraging their expertise and state-of-the-art facilities, Shin Nippon Biomedical Laboratories Ltd continually strives to contribute to society by providing innovative solutions for a healthier future.

Shin Nippon Biomedical Laboratories Ltd is primarily present in Japan, with its headquarters based in Tokyo.

Shin Nippon Biomedical Laboratories Ltd has achieved several significant milestones in its journey. The company has made remarkable advancements in the field of biomedical research and development. It has successfully developed and launched innovative pharmaceutical products, contributing to the improvement of global healthcare. Furthermore, Shin Nippon Biomedical Laboratories Ltd has forged strategic partnerships with renowned medical institutions, enhancing its capabilities and expanding its reach in the industry. By consistently delivering high-quality solutions, the company has gained recognition as a leader in the biomedical sector. Its commitment to excellence and continuous innovation has played a pivotal role in its success story.

Shin Nippon Biomedical Laboratories Ltd. (SNBL) is a renowned pharmaceutical research organization with a rich history and background. Founded in 1957, SNBL has emerged as a global leader in preclinical contract research, providing innovative drug development solutions to pharmaceutical, biotechnology, and medical device companies worldwide. With a strong focus on animal studies, SNBL utilizes its state-of-the-art facilities and expertise to conduct various safety and efficacy studies for the development of new therapeutics. Additionally, SNBL offers comprehensive toxicology, pathology, and bioanalysis services, ensuring regulatory compliance and efficient drug development processes. Through their commitment to excellence and customer satisfaction, SNBL continues to contribute significantly to advancements in pharmaceutical research and development.

The main competitors of Shin Nippon Biomedical Laboratories Ltd in the market include Charles River Laboratories International Inc., Covance Inc., and Laboratory Corporation of America Holdings (LabCorp).

Shin Nippon Biomedical Laboratories Ltd is primarily active in the pharmaceutical and biomedical industries.

Shin Nippon Biomedical Laboratories Ltd is a company that operates in the field of contract research services. Their business model primarily focuses on providing various research and development solutions for biopharmaceutical companies. Shin Nippon Biomedical Laboratories offers a wide range of services including preclinical and clinical studies, pharmacokinetics analysis, toxicology evaluations, and data management. By offering these comprehensive research services, the company aims to assist their clients in the development of new drugs and medical treatments. Shin Nippon Biomedical Laboratories' dedication to providing high-quality research solutions has established them as a trusted partner in the biopharmaceutical industry.

مُعامل القيمة السوقية إلى الأرباح لـ Shin Nippon Biomedical Laboratories هو ٨٫٥١.

مُعامِل القيمة إلى المبيعات Shin Nippon Biomedical Laboratories هو ١٫٧٨.

نقاط جودة AlleAktien لـ Shin Nippon Biomedical Laboratories هي 5/10.

Shin Nippon Biomedical Laboratories الإيرادات هي ٢٦٫٤٥ مليارات JPY.

صافي الربح Shin Nippon Biomedical Laboratories هو ٥٫٥٣ مليارات JPY.

Shin Nippon Biomedical Laboratories (SNBL) Ltd is a leading biopharmaceutical company specializing in the development and manufacturing of medical products and services. SNBL was founded in Japan in 1957 and is now operating globally. The company offers a wide range of products and services based on three main areas: Preclinical, Clinical, and Laboratory. In the Preclinical area, SNBL provides various services aimed at evaluating the efficacy and safety of drugs and biotechnology products. This includes conducting studies on animals and supporting clients in preclinical drug development. SNBL has a wide range of devices and advanced technologies used in conducting these studies. Clients have access to a wide range of in vivo toxicity tests, genotoxicity tests, pharmacodynamics and pharmacokinetics studies, as well as other customized tests. SNBL's Preclinical team supports clients in the preclinical drug development process, from study design to approval. SNBL has several locations in Europe, Asia, and North America and conducts its studies according to applicable standards and regulations. In the Clinical area, SNBL provides support and services for conducting clinical trials. SNBL has multiple clinical research facilities around the world where a wide range of study types can be conducted, such as First-in-Human studies or Phase I-IV clinical trials. SNBL also offers specialized services for studies such as patient recruitment, biomarker analysis, and data management. SNBL is a competent partner for clients looking to conduct clinical trials for their pharmaceutical products. SNBL's clinical studies meet the requirements of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other globally operating regulatory authorities. SNBL's Laboratory division offers comprehensive services for analytical testing and quality control, particularly for pharmaceutical products. SNBL's laboratories cover a wide spectrum of analytical tests for the manufacturing and release of drugs, biotechnology products, medical devices, and diagnostics. SNBL has state-of-the-art laboratory equipment and experienced staff to provide customer-oriented services. Clients can access powerful analytical tests such as stability testing, impurities analysis, release testing, biological activity, and bioequivalence testing. SNBL's business model is based on a combination of high-quality products and customer-oriented services. SNBL understands the needs of its clients and offers tailored services that meet the highest standards and regulations. With its wide range of products and services, SNBL is able to meet the needs of its clients in every phase of drug development. SNBL works closely with its clients to achieve a fast and successful market launch of new drugs and diagnostics.

يوزع Shin Nippon Biomedical Laboratories أرباحًا قدرها ٥٠٫٠٠ JPY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Shin Nippon Biomedical Laboratories في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـShin Nippon Biomedical Laboratories هو JP3379950003.

رمز WKN لـ Shin Nippon Biomedical Laboratories هو A0BMJN.

الرمز المُختصر لـ Shin Nippon Biomedical Laboratories هو 2395.T.

خلال آخر 12 شهراً، دفعت Shin Nippon Biomedical Laboratories توزيعات أرباح بقيمة ٥٠٫٠٠ JPY . وهذا يعادل عائد توزيعات أرباح يقارب ٤٫٤٢ %. ومن المتوقع أن تدفع Shin Nippon Biomedical Laboratories خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٦٤٫٣١ JPY.

نسبة توزيعات الأرباح الحالية لـ Shin Nippon Biomedical Laboratories هي ٤٫٤٢ %.

Shin Nippon Biomedical Laboratories يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر أكتوبر, أبريل, أكتوبر, أبريل.

Shin Nippon Biomedical Laboratories دفعت توزيعات الأرباح كل عام خلال الـ9 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٦٤٫٣١ JPY. وهذا يعادل عائد توزيعات أرباح قدره ٥٫٦٩ %.

Shin Nippon Biomedical Laboratories يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٢٠ JPY من Shin Nippon Biomedical Laboratories المُعلن عنها في ١‏/١٢‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١٢‏/٢٠٢٤.

في العام 2023، وزعت Shin Nippon Biomedical Laboratories ٥٠ JPY كأرباح أسهم.

يتم توزيع أرباح Shin Nippon Biomedical Laboratories بالعملة JPY.